^
    Back
    Association details:
    Biomarker:FGFR1 expression
    Cancer:Urothelial Cancer
    Drug:rogaratinib (BAY 1163877) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

    Excerpt:
    ...- High FGFR 1/3 mRNA expression levels (RNAscope score of 3+ or 4+; measurement is part of the protocol) in archival or fresh tumor biopsy specimen...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.

    Excerpt:
    Selected patients were treated with rogaratinib 800mg twice daily...Eleven of 12 pts with a PR were positive for FGFR3 mRNA, 5 of whom also had FGFR3 mutations, and one patient was positive for FGFR1 mRNA.
    DOI:
    10.1200/JCO.2018.36.6_suppl.494
    Trial ID:
    NCT01976741